Trials
3 active
10 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ISL/ULO fixed-dose combination 2 mg/200 mg oral tablet administered qw for 96 weeks”In the company’s words, NCT07266831 on ClinicalTrials.gov
- Tested for
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection (2 trials), Hepatic Insufficiency
- Main trialPhase 2/3
- “Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to…”In the company’s words, NCT07266831 on ClinicalTrials.gov
- Other names
- MK-8507 · ULO
Other drugs for Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- ACC017Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Phase 3
- AlimatravirMerck & Co. · Phase 3
- IslatravirMerck & Co. · Phase 2/3
- ISL/ULOMerck & Co. · Phase 2/3
- CabotegravirViiV Healthcare · Phase 3
- DOVATOViiV Healthcare · Phase 3
Coming up3
- 29 Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- 10 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- 1 Feb 2029Phase 2/3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 10 NovStatus changed: Recruiting to Completed · ClinicalTrials.gov NCT07595263
- 10 NovCompletion date moved: 2027-01-15 to 2026-09-29 · ClinicalTrials.gov NCT07595263
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 1 Feb 2029 | A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) | |
| Phase 2Active, not recruiting | 10 Aug 2027 | A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060) | |
| Phase 1Not yet recruiting | 29 Jun 2027 | Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) | |
| Phase 2Completed | 30 Jan 2025 | Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013] | |
| Phase 1Completed | 16 Jul 2015 | Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003) | |
| Phase 1Completed | 23 Jun 2024 | A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016) | |
| Phase 1Completed | 11 Nov 2025 | A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006) | |
| Phase 1Completed | 9 Apr 2026 | A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012) | |
| Phase 1Completed | 23 May 2026 | A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018) | |
| Phase 1Completed | 29 Sep 2026 | A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026